RFK Jr. Halts Alzheimer’s‑Prevention Panel, Fueling a Policy Firestorm

Robert F. Kennedy Jr., who recently took the helm of the Department of Health and Human Services, has effectively put the brakes on the nation’s premier preventive‑care panel, the U.S. Preventive Services Task Force (USPSTF). The group, which usually gathers three times a year, hasn’t been able to reconvene since March 2025, leaving a crucial Alzheimer’s‑screening recommendation in limbo.

“The evidence for dementia screening is not particularly strong,” says John Ruiz, a clinical‑psychology professor at the University of Arizona and a former task‑force member. He added that the panel had already asked for more funding to solidify the evidence base, but without a meeting those recommendations can’t be released.

Kennedy has been vocal about what he calls “regulatory malpractice” surrounding early Alzheimer’s detection, yet he simultaneously dismissed the USPSTF’s leadership in May and refused to appoint replacements for expired seats. The result? The next scheduled meeting won’t happen until late August, and even then the panel may be a shadow of its former self, with up to eight new members who have yet to be vetted.

Health‑policy observers are sounding the alarm. Aaron Carroll, CEO of AcademyHealth, told Politico that Kennedy could be trying to reshape the independent task force the same way he overhauled the Advisory Committee on Immunization Practices—by ousting all existing members and installing skeptics. “There’s a risk the USPSTF could become less evidence‑based,” Carroll warned.

Why does this matter to everyday Americans? The USPSTF’s letter grades (A‑D) dictate which preventive services insurers must cover without a copay. If Alzheimer’s screening is downgraded—or left unaddressed—insurance may not foot the bill, leaving patients to shoulder out‑of‑pocket costs for tests whose benefit is still debated.

Alzheimer’s disease already touches more than 7 million people in the United States, making it the most common form of dementia. Early detection could become a game‑changer as new therapies emerge that work best before substantial cognitive decline sets in. Yet the medical community remains split: “You get ten neurologists, you get ten approaches,” Ruiz noted.

The controversy unfolds against a backdrop of broader tensions in Alzheimer’s research. Kennedy has repeatedly claimed we could have a cure today if not for “corruption” at the National Institutes of Health. Ironically, 14 of the nation’s 35 Alzheimer’s Disease Research Centers reported funding delays in March 2025 after NIH grant approvals stalled, forcing labs to cut staff and pause studies.

Critics, including the Alzheimer’s Impact Movement, have accused Kennedy of spreading misinformation and demanded an apology to patients and families. In response, an HHS spokesperson reiterated the department’s “commitment to advancing research in Alzheimer’s disease and other serious health conditions.”

As the August meeting approaches, all eyes will be on whether the USPSTF can regain its footing, or if Kennedy’s push for a “breakthrough” will leave the panel sidelined—and the nation’s most vulnerable patients waiting.